Communiqués CVRx, Inc.

Actions

CVRX

US1266381052

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
3,370 ^USD	+6,98%		+22,55%	-52,54%

25/08	Jorey Chernett adresse une lettre au conseil d'administration de CVRx	CI
24/08	Jorey Chernett exhorte le conseil d'administration à lancer un processus de vente	CI

Communiqués

25/08	CVRx Responds to Letter from Pointillist Family Office	AQ
24/08	CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy	AQ
11/08	CVRx Announces Sales Leadership Transition	AQ
07/08	CVRx : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
07/08	CVRx: Q2 Earnings Snapshot	AQ
06/08	CVRx Reports Second Quarter 2026 Financial and Operating Results	AQ
28/07	CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference	AQ
23/07	CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026	AQ
09/06	CVRx Announces Chief Financial Officer Transition	AQ
27/05	CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	AQ
20/05	CVRx to Present at the William Blair 46th Annual Growth Stock Conference	AQ
14/05	CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy	AQ
11/05	CVRx: Q1 Earnings Snapshot	AQ
11/05	CVRx Reports First Quarter 2026 Financial and Operating Results	AQ
04/05	CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population	AQ
27/04	CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026	AQ
20/04	CVRx Announces Nomination of Michael Dale for Election to the Board of Directors	AQ
13/04	CVRx Reports Preliminary First Quarter 2026 Financial Results	AQ
02/03	CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting	AQ
12/02	CVRx: Q4 Earnings Snapshot	AQ
12/02	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results	AQ
29/01	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026	AQ
22/01	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population	AQ
12/01	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance	AQ
06/01	CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy	AQ